Spots Global Cancer Trial Database for A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
Official Title: A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer
Study ID: NCT02463994
Conditions
Study Description
Brief Summary: The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an antibody against PD-L1. PD-L1 is expressed on lung cancers and is known to block the effects of the body's immune system in attacking the cancer. Blocking this PD-L1 has been shown to improve the body's immune cells to attack and kill the cancer cells in non-small cell lung cancer. The goal of this study is to see if prior treatment with radiation will allow improved recognition of the cancer by the body's immune cells in the presence of MPDL3280A.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
University of Washington, Seattle, Seattle, Washington, United States
Contact Details
Name: Nithya Ramnath, M.D.
Affiliation: University of Michigan Rogel Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
